The FDA did not request additional clinical or non-clinical data
The treatment could benefit 500 people with follicular lymphoma
Longer-term follow-up data from CARTITUDE-1 study show an overall response rate of 100% while 86% experienced a complete […]
Updated Date: Wed, 06 May 2020 00:00:00 EDT
Updated Date: Wed, 06 May 2020 00:00:00 EDT
Updated Date: Wed, 06 May 2020 00:00:00 EDT
Updated Date: Wed, 06 May 2020 00:00:00 EDT
Updated Date: Wed, 06 May 2020 00:00:00 EDT
Pfizer and Astellas’ Xtandi is already approved to treat non-metastatic castration-resistant prostate cancer, thanks to data showing it […]